Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 20, 2013, Pages 2831-2836

  Andrisani, Gianluca ^a   Marzo, M ^a   Celleno, L ^b   Guidi, L ^a   Papa, A ^a   Gasbarrini, A ^a   Armuzzi, A ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Crohn's disease; Infliximab; Psoriasis scalp with alopecia; Ustekinumab

Indexed keywords

C REACTIVE PROTEIN; CLOBETASOL PROPIONATE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; PREDNISONE; USTEKINUMAB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ALOPECIA; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HAIR LOSS; HUMAN; LEUKOCYTE COUNT; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAKERATOSIS; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; PSORIASIS; REMISSION; SCALP PSORIASIS; SKIN BIOPSY; SMALL INTESTINE PERFORATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALOPECIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890517982     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. GOTTLIEB AB, EVANS R, LI S, DOOLEY LT, GUZZO CA, BAKER D, BALA M, MAARANO CW, MENTER A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
2. MENTER A, TYRING SK, GORDON K, KIMBALL AB, LEONARDI CL, LANGLEY RG, STROBER BE, KAUL M, GU Y, OKUN M, PAPP K. Adalimumab therapy for moderate to severe psoriasis: a randomized controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
3. SAURAT JH, STINGL G, DUBERTRET L, PAPP K, LANGLEY RG, ORTONNE JP, UNNEBRINK K, KAUL M, CAMEZ A. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
4. PAPP K, BERTH-JONES J, KRAGBALLE K, WOZEL G, DE LA BRASSINNE M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21: 1151-1160.
5. VAN DE KERKHOF PC, DE HOOP D, DE KORTE J, KUIPER MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326-334.
6. SANDBORN WJ, FEAGAN BG, FEDORAK RN, SCHERL E, FLEISHER MR, KATZ S, JOHANNS J, BLANK M, RUTGEERTS P; FOR USTEKINUMAB CROHN'S DISEASE STUDY GROUP. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
7. SANDBORN WJ, GASINK C, GAO LL, BLANK MA, JOHANNS J, GUZZO C, SANDS BE, HANAUER SB, TARGAN S, RUTGEERTS P, GHOSH S, DE VILLIERS WJ, PANACCIONE R, GREENBERG G, SCHREIBER S, LICHTIGER S, FEAGAN BG; CERTIFI STUDY GROUP. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528.
8. COLLAMER AN, BATTAFARANO DO. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-240.
9. SFIKAKIS PP, KOLLIAS G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 380-386.
10. COLLAMER AN, GUERRERO KT, HENNING JS, BATTAFARANO DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.
11. DE GANNES G, GHOREISHI M, POPE J, RUSSELL A, BELL D, ADAMS S, SHOJANIA K, MARTINKA M, DUTZ JP. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic contidions. Arch Dermatol 2007; 143: 223-231.
12. SHABRAWI-CAELEN L, LA PLACA M, VINCENZI C, HAIDN T, MUELLEGGER R, TOSTI A. Adalimumab induced psoriasis of the scalp with diffuse alopecia:a severe potentially irreversible cutaneous side effect of TNF alpha blockers. Inflamm Bowel Dis 2010; 16: 182-183.
13. GILLIET M, CONRAD C, GEIGES M, COZZIO A, THÜRLIMANN W, BURG G, NESTLE FO, DUMMER R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-1495.
14. NESTLE FO, KAPLAN DH, BARKER J. Psoriasis. N Engl J Med 2009: 361: 496-509.
15. WOLLINA U, HANSEL G, KOCH A, SCHÖNLEBE J, KÖSTLER E, HAROSKE G. Tumor necrosis factor a inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.
16. SHMIDT E, WETTER DA, FERGUSON SB, PITTELKOW MR. Psoriasis and palmoplantars pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clini experience, 1998 to 2010. J Am Acad Dermatol 2012; 67: e179-185.
17. RAHIER JF, BUCHE S, PEYRIN-BIROULET L, BOUHNIK Y, DUCLOS B, LOUIS E, PAPAY P, ALLEZ M, COSNES J, CORTOT A, LAHARIE D, REIMUND JM, LÉMANN M, DELAPORTE E, COLOMBEL JF; GROUPE D'ETUDE THÉRAPEUTIQUE DES AFFECTIONS INFLAMMATOIRES DU TUBE DIGESTIF (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue antitumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8: 1048-1055.
18. CONKLIN LS, COHEN B, WILSON L, CUFFARI C, OLIVAHEMKER M. Rash induced by anti tumor necrosis factor agents in an adolescent with Crohn's disease. Nat. Rev Gastroenterol Hepatol 2010; 7: 174-177.
19. FIORINO G, ALLENZ M, MALESCI A, DANESE S. Review article: anti TNF alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-927.
20. AVILA ALVAREZ A, GARCÌA -ALONSO L, SOLAR BOGA A, SOLAR BOGA A, GARCÍA-SILVA J. Flexural psoriasis induced by infliximab and adalimumab in patient with Crohn's disease. An Pediatric (Barc) 2009; 70: 278-281.
21. TICHY M JR, TICHY M, KOPOVA R, STERNBERSKY J, DITRICHOVA D. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease. J Dermatolog Treat 2012; 23: 208-211.
22. BUISSON A, CUNY JF, BARBAUD A, SCHMUTZ JL, BIGARD MA, GUÉANT JL, PEYRIN-BIROULET L. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1175-1180.
23. LEONARDI CL, KIMBALL AB, PAPP KA, YEILDING N, GUZZO C, WANG Y, LI S, DOOLEY LT, GORDON KB; PHOENIX 1 STUDY INVESTIGATORS. Efficacy and safety of ustekinumab, a human interleukin-12\23 monoclonal antibody, in patients with psoriasis:76-week results from randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
24. PAPP KA, LANGLEY RG, LEBWOHL M, KRUEGER GG, SZAPARY P, YEILDING N, GUZZO C, HSU MC, WANG Y, LI S, DOOLEY LT, REICH K; PHOENIX 2 STUDY INVESTIGATORS. Efficacy and safety of ustekinumab, a human interleukin-12\23 monoclonal antibody, in patients with psoriasis:52-week results from randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
25. GRIFFINTHS CE, STROBER BE, VAN DE KERKHOF P, HO V, FIDELUS-GORT R, YEILDING N, GUZZO C, XIA Y, ZHOU B, LI S, DOOLEY LT, GOLDSTEIN NH, MENTER A; ACCEPT STUDY GROUP. Comparison of ustekinumab and etanercept for moderate-to-severe plaque psoriasis. N Engl J Med 2010: 362: 118-128.
26. DUERR RH, TAYLOR KD, BRANT SR, BRANT SR, RIOUX JD, SILVERBERG MS, DALY MJ, STEINHART AH, ABRAHAM C, REGUEIRO M, GRIFFITHS A, DASSOPOULOS T, BITTON A, YANG H, TARGAN S, DATTA LW, KISTNER EO, SCHUMM LP, LEE AT, GREGERSEN PK, BARMADA MM, ROTTER JI, NICOLAE DL, CHO JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
27. STROBER W, ZHANG F, KITANI A, FUSS I, FICHTNER-FEIGL S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010; 26: 310-317.
28. BERREBI D, BESNARD M, FROMONT-HANKARD G, PARIS R, MOUGENOT JF, DE LAGAUSIE P, EMILIE D, CEZARD JP, NAVARRO J, PEUCHMAUR M. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease Am J Pathol 1998; 152: 667-672.